Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19.
作者信息
Wang Liqin, Foer Dinah, Bates David W, Boyce Joshua A, Zhou Li
机构信息
Divisions of General Internal Medicine and Primary Care, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.
Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Mass.
出版信息
J Allergy Clin Immunol. 2020 Oct;146(4):808-812. doi: 10.1016/j.jaci.2020.07.018. Epub 2020 Jul 29.
Abstract
摘要
相似文献
1
Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19.哮喘合并新型冠状病毒肺炎患者住院、重症监护及死亡的危险因素。
J Allergy Clin Immunol. 2020 Oct;146(4):808-812. doi: 10.1016/j.jaci.2020.07.018. Epub 2020 Jul 29.
2
The "Three Italy" of the COVID-19 epidemic and the possible involvement of SARS-CoV-2 in triggering complications other than pneumonia.新冠疫情“三意大利”现象及 SARS-CoV-2 可能引发除肺炎外的并发症。
J Neurovirol. 2020 Jun;26(3):311-323. doi: 10.1007/s13365-020-00862-z. Epub 2020 Jun 16.
3
Adaptation of a Russian population to SARS-CoV-2: Asymptomatic course, comorbidities, mortality, and other respiratory viruses - A reply to Fear versus Data.俄罗斯人群对 SARS-CoV-2 的适应：无症状病程、合并症、死亡率和其他呼吸道病毒——对“恐惧与数据”的回应。
Int J Antimicrob Agents. 2020 Oct;56(4):106093. doi: 10.1016/j.ijantimicag.2020.106093. Epub 2020 Jul 10.
4
Characteristics and Outcomes of Coronavirus Disease Patients under Nonsurge Conditions, Northern California, USA, March-April 2020.2020 年 3 月至 4 月，美国北加州非紧急状况下的冠状病毒疾病患者的特征和结局。
Emerg Infect Dis. 2020 Aug;26(8):1679-1685. doi: 10.3201/eid2608.201776. Epub 2020 May 14.
5
Comorbidities and Mortality in Patients With COVID-19 Aged 60 Years and Older in a University Hospital in Spain.西班牙一家大学医院中60岁及以上新冠病毒疾病患者的合并症与死亡率
Arch Bronconeumol (Engl Ed). 2020 Nov;56(11):756-758. doi: 10.1016/j.arbres.2020.06.012. Epub 2020 Jul 16.
6
Foreword for the special issue advances in COVID-19: Biology and clinic.《新冠病毒：生物学与临床进展》特刊前言
Adv Biol Regul. 2020 Aug;77:100744. doi: 10.1016/j.jbior.2020.100744. Epub 2020 Jul 9.
7
Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study.过敏疾病与 COVID-19 的易感性和严重程度：一项全国性队列研究。
J Allergy Clin Immunol. 2020 Oct;146(4):790-798. doi: 10.1016/j.jaci.2020.08.008. Epub 2020 Aug 15.
8
Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19.COVID-19 住院和非住院患者中哮喘的患病率和特征。
J Allergy Clin Immunol. 2020 Aug;146(2):307-314.e4. doi: 10.1016/j.jaci.2020.06.010. Epub 2020 Jun 15.
9
Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico.墨西哥大型数据集内 COVID-19 患者的临床特征和死亡风险因素。
Ann Epidemiol. 2020 Dec;52:93-98.e2. doi: 10.1016/j.annepidem.2020.08.005. Epub 2020 Aug 14.
10
IMPACT OF COMORBIDITIES IN MEXICAN SARS-COV-2-POSITIVE PATIENTS: A RETROSPECTIVE ANALYSIS IN A NATIONAL COHORT.墨西哥新冠病毒检测呈阳性患者中合并症的影响：一项全国队列的回顾性分析
Rev Invest Clin. 2020;72(3):151-158. doi: 10.24875/RIC.20000207.
引用本文的文献
1
Key Characteristics of Asthma Patients with COVID-19 Vary Substantially by Age.感染新冠病毒的哮喘患者的关键特征因年龄而异。
J Asthma Allergy. 2024 Jun 22;17:589-600. doi: 10.2147/JAA.S456145. eCollection 2024.
2
Assessing fairness in machine learning models: A study of racial bias using matched counterparts in mortality prediction for patients with chronic diseases.评估机器学习模型的公平性：使用慢性病患者死亡率预测中的匹配对照研究种族偏见。
J Biomed Inform. 2024 Aug;156:104677. doi: 10.1016/j.jbi.2024.104677. Epub 2024 Jun 13.
3
Clinical features in patients with COVID-19 treated with biologics for severe asthma.使用生物制剂治疗重症哮喘的新冠肺炎患者的临床特征。
J Allergy Clin Immunol Glob. 2024 Jan 28;3(2):100219. doi: 10.1016/j.jacig.2024.100219. eCollection 2024 May.
4
The influence of prior use of inhaled corticosteroids on COVID-19 outcomes: A systematic review and meta-analysis.既往使用吸入性皮质类固醇对 COVID-19 结局的影响：系统评价和荟萃分析。
PLoS One. 2024 Jan 19;19(1):e0295366. doi: 10.1371/journal.pone.0295366. eCollection 2024.
5
Outcomes of COVID-19 amongst patients with ongoing use of inhaled corticosteroids - a systematic review & meta-analysis.持续使用吸入性糖皮质激素的 COVID-19 患者的预后——一项系统评价与荟萃分析
Infez Med. 2023 Dec 1;31(4):440-448. doi: 10.53854/liim-3104-3. eCollection 2023.
6
Characteristics and outcomes of adult patients with asthma presenting with COVID-19: A comparative cohort study.患有 COVID-19 的成年哮喘患者的特征与结局：一项比较队列研究。
Qatar Med J. 2023 Aug 8;2023(3):15. doi: 10.5339/qmj.2023.15. eCollection 2023.
7
Post-Acute COVID-19 Respiratory Symptoms in Patients With Asthma: An Electronic Health Records-Based Study.哮喘患者 COVID-19 后呼吸道症状：一项基于电子健康记录的研究。
J Allergy Clin Immunol Pract. 2023 Mar;11(3):825-835.e3. doi: 10.1016/j.jaip.2022.12.003. Epub 2022 Dec 22.
8
Effects of COVID-19 and Social Distancing on Rhinovirus Infections and Asthma Exacerbations.新冠疫情和社交隔离对鼻病毒感染和哮喘恶化的影响。
Viruses. 2022 Oct 25;14(11):2340. doi: 10.3390/v14112340.
9
Effect of asthma, COPD, and ACO on COVID-19: A systematic review and meta-analysis.哮喘、COPD 和 ACO 对 COVID-19 的影响：系统评价和荟萃分析。
PLoS One. 2022 Nov 1;17(11):e0276774. doi: 10.1371/journal.pone.0276774. eCollection 2022.
10
Epigenetic mechanisms and host factors impact ACE2 gene expression: Implications in COVID-19 susceptibility.表观遗传机制和宿主因素影响 ACE2 基因表达：在 COVID-19 易感性中的意义。
Infect Genet Evol. 2022 Oct;104:105357. doi: 10.1016/j.meegid.2022.105357. Epub 2022 Aug 28.
本文引用的文献
1
Characteristics of Hospitalized Adults With COVID-19 in an Integrated Health Care System in California.加利福尼亚州综合医疗保健系统中 COVID-19 住院成人的特征。
JAMA. 2020 Jun 2;323(21):2195-2198. doi: 10.1001/jama.2020.7202.
2
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.在纽约市地区，5700 名因 COVID-19 住院的患者的特征、合并症和结局。
JAMA. 2020 May 26;323(20):2052-2059. doi: 10.1001/jama.2020.6775.
3
COVID-19 with Different Severities: A Multicenter Study of Clinical Features.不同严重程度的 COVID-19：一项多中心临床特征研究。
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1380-1388. doi: 10.1164/rccm.202002-0445OC.
4
Clinical Course and Outcomes of 344 Intensive Care Patients with COVID-19.344例新冠肺炎重症监护患者的临床病程及预后
Am J Respir Crit Care Med. 2020 Jun 1;201(11):1430-1434. doi: 10.1164/rccm.202003-0736LE.
5
Hospitalization and Critical Care of 109 Decedents with COVID-19 Pneumonia in Wuhan, China.中国武汉 109 例 COVID-19 肺炎逝者的住院和重症监护情况
Ann Am Thorac Soc. 2020 Jul;17(7):839-846. doi: 10.1513/AnnalsATS.202003-225OC.
6
Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection?慢性呼吸道疾病或其治疗是否会影响感染SARS-CoV-2的风险？
Lancet Respir Med. 2020 May;8(5):436-438. doi: 10.1016/S2213-2600(20)30167-3. Epub 2020 Apr 3.
7
Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 - United States, February 12-March 28, 2020.2019 年冠状病毒病患者中某些基础健康状况的初步估计——美国，2020 年 2 月 12 日至 3 月 28 日。
MMWR Morb Mortal Wkly Rep. 2020 Apr 3;69(13):382-386. doi: 10.15585/mmwr.mm6913e2.
8
Prevalence and contribution of respiratory viruses in the community to rates of emergency department visits and hospitalizations with respiratory tract infections, chronic obstructive pulmonary disease and asthma.呼吸道病毒在社区中流行情况及其对呼吸道感染、慢性阻塞性肺疾病和哮喘急诊就诊率和住院率的影响。
PLoS One. 2020 Feb 6;15(2):e0228544. doi: 10.1371/journal.pone.0228544. eCollection 2020.
9
IL-33 drives influenza-induced asthma exacerbations by halting innate and adaptive antiviral immunity.IL-33 通过阻断先天和适应性抗病毒免疫来驱动流感诱导的哮喘恶化。
J Allergy Clin Immunol. 2019 Apr;143(4):1355-1370.e16. doi: 10.1016/j.jaci.2018.08.051. Epub 2018 Oct 12.
Zotero 插件